This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

USPTO’s patent invalidity rate a red herring, study says

By Nick Robertson ( July 9, 2025, 21:28 GMT | Insight) -- The Patent Trial and Appeal Board’s high patent invalidity rate doesn’t prove that the US Patent and Trademark Office is granting weak patents, but rather that the system is working as intended, two academics argued in a recent paper. The thesis is a direct rejection of the loudest argument against the PTAB.The Patent Trial and Appeal Board isn’t the “patent death squad” it is sometimes argued to be by its fiercest critics, a pair of academics argued in a recent paper that aims to shoot holes in one of the loudest arguments for rolling back the nearly-15-year-old review board....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections